CHF65.30
3.82% today
SIX Swiss Exchange, Sep 01, 05:30 pm CET
ISIN
NL0011832936
Symbol
COPN

COSMO Pharmaceuticals Stock price

CHF65.30
+6.80 11.62% 1M
-1.10 1.66% 6M
+1.60 2.51% YTD
-14.60 18.27% 1Y
+14.30 28.04% 3Y
-29.60 31.19% 5Y
-112.70 63.31% 10Y
+43.00 192.83% 20Y
SIX Swiss Exchange, Closing price Mon, Sep 01 2025
+2.40 3.82%
ISIN
NL0011832936
Symbol
COPN
Industry

Key metrics

Basic
Market capitalization
CHF1.1b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
19.5 | 32.0
P/S
6.2 | 7.4
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
CHF1.95
Yield 1Y | 5Y
3.1% | 1.3%
Growth 1Y | 5Y
100.0% | -
Payout 1Y | 3Y
0.0% | 25.1%
Increased
1 Year
Financials (TTM | estimate)
Revenue
CHF170.5m | CHF142.2m
EBITDA
CHF68.2m | CHF83.0m
EBIT
CHF56.6m | CHF121.6m
Net Income
CHF51.7m | -
Free Cash Flow
CHF62.5m
Growth (TTM | estimate)
Revenue
-1.7% | -43.0%
EBITDA
-9.7% | -41.1%
EBIT
-13.2% | -12.7%
Net Income
-6.3% | -
Free Cash Flow
-31.8%
Margin (TTM | estimate)
Gross
73.8%
EBITDA
40.0% | 58.4%
EBIT
33.2%
Net
30.3% | -
Free Cash Flow
36.6%
Financial Health
Equity Ratio
77.1%
Return on Equity
26.7%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
CHF3.2
FCF per Share
-
Short interest
-
Employees
322
Rev per Employee
CHF780.0k
Show more

Is COSMO Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

COSMO Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a COSMO Pharmaceuticals forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a COSMO Pharmaceuticals forecast:

Buy
91%
Hold
9%

Financial data from COSMO Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
171 171
2% 2%
100%
- Direct Costs 45 45
10% 10%
26%
126 126
5% 5%
74%
- Selling and Administrative Expenses 32 32
6% 6%
19%
- Research and Development Expense 44 44
23% 23%
26%
68 68
10% 10%
40%
- Depreciation and Amortization 12 12
12% 12%
7%
EBIT (Operating Income) EBIT 57 57
13% 13%
33%
Net Profit 52 52
6% 6%
30%

In millions CHF.

Don't miss a Thing! We will send you all news about COSMO Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Head office Netherlands
CEO Giovanni Napoli
Employees 322
Founded 2016
Website www.cosmopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today